The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension
- PMID: 33735262
- PMCID: PMC7971559
- DOI: 10.1371/journal.pone.0248652
The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension
Abstract
Background: A number of studies have reported the association between the use of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin-II receptor blocker (ARB) medications and the occurrence or severity of coronavirus disease 2019 (COVID-19). Published results are inconclusive, possibly due to differences in participant comorbidities and sociodemographic backgrounds. Since ACEI and ARB are frequently used anti-hypertension medications, we aim to determine whether the use of ACEI and ARB is associated with the occurrence and severity of COVID-19 in a large study of US Veterans with hypertension.
Methods: Data were collected from the Department of Veterans Affairs (VA) National Corporate Data Warehouse (VA-COVID-19 Shared Data Resource) between February 28, 2020 and August 18, 2020. Using data from 228,722 Veterans with a history of hypertension who received COVID-19 testing at the VA, we investigated whether the use of ACEI or ARB over the two years prior to the index date was associated with increased odds of (1) a positive COVID-19 test, and (2) a severe outcome (hospitalization, mortality, and use of intensive care unit (ICU) and/or mechanical ventilation) among COVID-19-positive patients. We used logistic regression with and without propensity score weighting (PSW) to estimate the odds ratio (OR) and 95% confidence interval (95% CI) for the association between ACEI/ARB use and a positive COVID-19 test result. The association between medication use and COVID-19 outcome severity was examined using multinomial logistic regression comparing participants who were not hospitalized to participants who were hospitalized, were admitted to the ICU, used a mechanical ventilator, or died. All models were adjusted for relevant covariates, including demographics (age, sex, race, ethnicity), selected comorbidities, and the Charlson Comorbidity Index (CCI).
Results: The use of ACEI significantly decreased the odds of a positive COVID-19 test among Veterans with hypertension (OR = 0.917, (0.887, 0.948) and OR = 0.926, (0.894, 0.958) with PSW). The use of ACEI, but not of ARB, was also associated with significantly increased odds of using mechanical ventilators (OR = 1.265, (1.010, 1.584) and OR = 1.210, (1.053, 1.39) with PSW) among all COVID-19 inpatients compared to outpatients.
Conclusions: In this study of Veterans with hypertension, ACEI was significantly associated with decreased odds of testing positive for COVID-19. With the exception of the association of ACEI with a small non-clinically-important increase in the odds of using mechanical ventilators, neither ACEI nor ARB was found to be associated with clinical severity or mortality among COVID-19-positive Veterans. The results of this study need further corroboration and validation in other cohort samples outside the VA.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
![Fig 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7971559/bin/pone.0248652.g001.gif)
![Fig 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7971559/bin/pone.0248652.g002.gif)
Similar articles
-
SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway.Cureus. 2024 Mar 5;16(3):e55563. doi: 10.7759/cureus.55563. eCollection 2024 Mar. Cureus. 2024. PMID: 38576704 Free PMC article. Review.
-
Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.Drugs. 2022 Jan;82(1):43-54. doi: 10.1007/s40265-021-01639-2. Epub 2021 Dec 16. Drugs. 2022. PMID: 34914085 Free PMC article.
-
Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system.Am Heart J. 2021 Oct;240:46-57. doi: 10.1016/j.ahj.2021.06.004. Epub 2021 Jun 12. Am Heart J. 2021. PMID: 34126079 Free PMC article.
-
Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.PLoS One. 2021 Apr 23;16(4):e0248080. doi: 10.1371/journal.pone.0248080. eCollection 2021. PLoS One. 2021. PMID: 33891615 Free PMC article.
-
Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.Curr Cardiol Rep. 2020 Apr 14;22(5):31. doi: 10.1007/s11886-020-01291-4. Curr Cardiol Rep. 2020. PMID: 32291526 Free PMC article. Review.
Cited by
-
The Comparative Effectiveness of Monotherapy and Combination Therapies: Impact of Angiotensin Receptor Blockers on the Onset of Alzheimer's Disease.JAR Life. 2023 Jun 20;12:35-45. doi: 10.14283/jarlife.2023.8. eCollection 2023. JAR Life. 2023. PMID: 37441415 Free PMC article.
-
Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease.Front Cell Infect Microbiol. 2023 May 3;13:1178590. doi: 10.3389/fcimb.2023.1178590. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37207192 Free PMC article.
-
Role of Angiotensin Converting Enzyme-2 and its modulation in disease: exploring new frontiers.Med Pharm Rep. 2023 Apr;96(2):146-153. doi: 10.15386/mpr-2345. Epub 2023 Apr 27. Med Pharm Rep. 2023. PMID: 37197279 Free PMC article. Review.
-
Exploration of multifaceted molecular mechanism of angiotensin-converting enzyme 2 (ACE2) in pathogenesis of various diseases.Heliyon. 2023 Apr 20;9(5):e15644. doi: 10.1016/j.heliyon.2023.e15644. eCollection 2023 May. Heliyon. 2023. PMID: 37153428 Free PMC article. Review.
-
Clinical effectiveness of medical ozone therapy in COVID-19: the evidence and gaps map.Med Gas Res. 2023 Oct-Dec;13(4):172-180. doi: 10.4103/2045-9912.372819. Med Gas Res. 2023. PMID: 37077114 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical